OKYO Pharma Ltd ADR (OKYO) - Total Liabilities
Based on the latest financial reports, OKYO Pharma Ltd ADR (OKYO) has total liabilities worth $8.64 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check OKYO Pharma Ltd ADR liquid asset ratio to evaluate the company's liquid asset resilience ratio.
OKYO Pharma Ltd ADR - Total Liabilities Trend (2008–2026)
This chart illustrates how OKYO Pharma Ltd ADR's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see OKYO Pharma Ltd ADR balance sheet assets.
OKYO Pharma Ltd ADR Competitors by Total Liabilities
The table below lists competitors of OKYO Pharma Ltd ADR ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Solidion Technology Inc.
NASDAQ:STI
|
USA | $10.69 Million |
|
Cactus Acquisition Corp 1 Ltd
NASDAQ:CCTS
|
USA | $2.27 Million |
|
MGI Digital
PA:ALMDG
|
France | €38.03 Million |
|
Sahamit Machinery Public Company Limited
BK:SMIT
|
Thailand | ฿306.32 Million |
|
Ginar Technology Co Ltd
TWO:6151
|
Taiwan | NT$569.81 Million |
|
Sentry Select Primary Metals Corp
TO:PME
|
Canada | CA$179.00K |
|
Heron Therapeuti
NASDAQ:HRTX
|
USA | $237.08 Million |
|
Ahoku Electronic Co
TW:3002
|
Taiwan | NT$504.39 Million |
Liability Composition Analysis (2008–2026)
This chart breaks down OKYO Pharma Ltd ADR's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See OKYO net asset quality score to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.43 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.70 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.41 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how OKYO Pharma Ltd ADR's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for OKYO Pharma Ltd ADR (2008–2026)
The table below shows the annual total liabilities of OKYO Pharma Ltd ADR from 2008 to 2026.
| Year | Total Liabilities | Change |
|---|---|---|
| 2026-03-31 | $8.64 Million | -6.35% |
| 2025-03-31 | $9.23 Million | +24.34% |
| 2024-03-31 | $7.42 Million | +2.26% |
| 2023-03-31 | $7.26 Million | +436.30% |
| 2022-03-31 | $1.35 Million | -23.63% |
| 2021-03-31 | $1.77 Million | +140.36% |
| 2020-03-31 | $737.20K | +72.76% |
| 2019-03-31 | $426.72K | +368.62% |
| 2018-03-31 | $91.06K | -64.81% |
| 2017-03-31 | $258.76K | +42.69% |
| 2016-03-31 | $181.34K | +20.04% |
| 2015-03-31 | $151.07K | -39.07% |
| 2014-03-31 | $247.95K | +35.25% |
| 2013-03-31 | $183.32K | -77.99% |
| 2012-03-31 | $832.89K | +957.75% |
| 2011-03-31 | $78.74K | -1.42% |
| 2010-03-31 | $79.87K | -7.08% |
| 2009-03-31 | $85.96K | -40.66% |
| 2008-03-31 | $144.86K | -- |
About OKYO Pharma Ltd ADR
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase II clinical trials for the treatment of dry eye disease; in Phase II clinical trial to treat neuropathic corneal pain; and is in preclinical trial to t… Read more